Biopharmaceutical Analysis & Statistics, January 2013 (p10)

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publishers

All regions

You might be interested in: Protein, Biomedical, Antibody, more »

271-310 of about 900 reports

Purchase Reports From Reputable Market Research Publishers

Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014

Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD279 (PD-1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the ...

  • Industries : Biopharmaceutical
Anti-CD28 Antibody -Pipeline Insights, 2014

Anti-CD28 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD28 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD3 Antibody -Pipeline Insights, 2014

Anti-CD3 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD3 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD30 Antibody -Pipeline Insights, 2014

Anti-CD30 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD30 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD33 Antibody -Pipeline Insights, 2014

Anti-CD33 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD33 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD37 Antibody -Pipeline Insights, 2014

Anti-CD37 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD37 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD38 Antibody -Pipeline Insights, 2014

Anti-CD38 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD38 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD4 Antibody -Pipeline Insights, 2014

Anti-CD4 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD4 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD40 Antibody -Pipeline Insights, 2014

Anti-CD40 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD40 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD52 Antibody -Pipeline Insights, 2014

Anti-CD52 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD52 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD6 Antibody -Pipeline Insights, 2014

Anti-CD6 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD6 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD70 Antibody -Pipeline Insights, 2014

Anti-CD70 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD70 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD80 Antibody -Pipeline Insights, 2014

Anti-CD80 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD80 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD95 Antibody -Pipeline Insights, 2014

Anti-CD95 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD95 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CS1 Antibody -Pipeline Insights, 2014

Anti-CS1 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CS1 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-Dickkopf-1 (Dkk-1) Antibody -Pipeline Insights, 2014

Anti-Dickkopf-1 (Dkk-1) Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-Dickkopf-1 (Dkk-1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective ...

  • Industries : Biopharmaceutical
Anti-Mucin 1 (MUC1) Antibody -Pipeline Insights, 2014

Anti-Mucin 1 (MUC1) Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-Mucin 1 (MUC1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of ...

  • Industries : Biopharmaceutical
ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors -Pipeline Insights, 2014

ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs ...

  • Industries : Biopharmaceutical
Bone Morphogenetic Protein (BMP) Receptor Activators -Pipeline Insights, 2014

Bone Morphogenetic Protein (BMP) Receptor Activators -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Bone Morphogenetic Protein (BMP) Receptor Activators-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). ...

  • Industries : Biopharmaceutical
Bcl-w Protein Inhibitors -Pipeline Insights, 2014

Bcl-w Protein Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Bcl-w Protein Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the ...

  • Industries : Biopharmaceutical
Bcl-xL Protein Inhibitors -Pipeline Insights, 2014

Bcl-xL Protein Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Bcl-xL Protein Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the ...

  • Industries : Biopharmaceutical
Cholesterylester Transfer Protein (CETP) Inhibitors -Pipeline Insights, 2014

Cholesterylester Transfer Protein (CETP) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Cholesterylester Transfer Protein (CETP) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). ...

  • Industries : Biopharmaceutical
Endothelin Converting Enzyme (ECE) Inhibitors -Pipeline Insights, 2014

Endothelin Converting Enzyme (ECE) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Endothelin Converting Enzyme (ECE) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A ...

  • Industries : Biopharmaceutical
Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors -Pipeline Insights, 2014

Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of ...

  • Industries : Biopharmaceutical
Factor IX -Pipeline Insights, 2014

Factor IX -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Factor IX-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish ...

  • Industries : Biopharmaceutical
Factor VIII Inhibitors -Pipeline Insights, 2014

Factor VIII Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Factor VIII Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Farnesyl Protein Transferase (FPTase) Inhibitors -Pipeline Insights, 2014

Farnesyl Protein Transferase (FPTase) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Farnesyl Protein Transferase (FPTase) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). ...

  • Industries : Biopharmaceutical
FK506 Binding Protein (FKBP) Inhibitors -Pipeline Insights, 2014

FK506 Binding Protein (FKBP) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“FK506 Binding Protein (FKBP) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective ...

  • Industries : Biopharmaceutical
Follicle-Stimulating Hormone Receptor (FSH Receptor or FSHR) Antagonists -Pipeline Insights, 2014

Follicle-Stimulating Hormone Receptor (FSH Receptor or FSHR) Antagonists -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Follicle-Stimulating Hormone Receptor (FSH Receptor or FSHR) Antagonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism ...

  • Industries : Biopharmaceutical
Factor IX A Inhibitors -Pipeline Insights, 2014

Factor IX A Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Factor IX A Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical

20 Companies

Read our Company Profiles

Johnson and Johnson

United States

Biogen Idec

United States

GlaxoSmithKline P.L.C.

United States

Abbott Laboratories

United States

Amgen Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.